1349 Stock Overview
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.69 |
| 52 Week High | HK$4.42 |
| 52 Week Low | HK$1.70 |
| Beta | 0.21 |
| 11 Month Change | 1.13% |
| 3 Month Change | 48.62% |
| 1 Year Change | 2.67% |
| 33 Year Change | -32.07% |
| 5 Year Change | n/a |
| Change since IPO | -42.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -5.6% | -2.0% | -2.7% |
| 1Y | 2.7% | -9.4% | 10.9% |
Return vs Industry: 1349 exceeded the Hong Kong Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned 10.9% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 16.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1349's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1349's weekly volatility has increased from 9% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 913 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market cap | HK$7.39b |
| Earnings (TTM) | HK$113.11m |
| Revenue (TTM) | HK$743.61m |
24.7x
P/E Ratio3.7x
P/S RatioIs 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥691.62m |
| Cost of Revenue | CN¥64.16m |
| Gross Profit | CN¥627.46m |
| Other Expenses | CN¥522.25m |
| Earnings | CN¥105.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 90.72% |
| Net Profit Margin | 15.21% |
| Debt/Equity Ratio | 0% |
How did 1349 perform over the long term?
See historical performance and comparison